Long-term Results of Dose Density Therapy in Patients With Aggressive Lymphoma

Ann Hematol. 2005 Apr;84(4):217-22. doi: 10.1007/s00277-004-0936-x. Epub 2004 Nov 6.

Abstract

To evaluate the long-term outcome of dose density chemotherapy in the treatment of aggressive lymphoma, we analyzed 142 patients with untreated aggressive lymphoma. Chemotherapy was an eight-drug regimen given in weekly intervals in two prospective trials. The median observation period was 8 years; the longest follow-up was 13 years. Overall survival at 8 years was 0.583. The 8-year survival of patients < or =60 years was significantly better than that of older patients, namely 0.713 vs 0.304 (p=0.000000697). This excellent survival of patients aged < or =60 years was identical for high-risk and high-intermediate-risk patients compared with low-risk and low-intermediate-risk patients in the age-adjusted international prognostic index (IPI). The excellent long-term results of the CEOP/IMVP-Dexa regimen (cyclophosphamide, epirubicin, vincristine, and prednisone/ifosfamide with systemic mesna, methotrexate, etoposide, and dexamethasone) for patients aged < or =60 years suggest that this regimen might be superior to the standard CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisolone) and needs to be tested in comparison to high-dose regimens and novel approaches including antibody treatment.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Age Factors
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Cause of Death
  • Cyclophosphamide / administration & dosage
  • Dexamethasone / administration & dosage
  • Epirubicin / administration & dosage
  • Etoposide / administration & dosage
  • Humans
  • Ifosfamide / administration & dosage
  • Longitudinal Studies
  • Lymphoma / drug therapy*
  • Mesna / administration & dosage
  • Methotrexate / administration & dosage
  • Middle Aged
  • Prednisone / administration & dosage
  • Survival Analysis
  • Treatment Failure
  • Treatment Outcome
  • Vincristine / administration & dosage

Substances

  • Epirubicin
  • Vincristine
  • Etoposide
  • Dexamethasone
  • Cyclophosphamide
  • Mesna
  • Ifosfamide
  • Prednisone
  • Methotrexate